Glenview Trust Co continued to hold its stake in C R Bard Inc (NYSE:BCR) during the first quarter, Holdings Channel reports. The fund owned 3,490 shares of the medical instruments supplier’s stock at the end of the first quarter. Glenview Trust Co’s holdings in C R Bard were worth $867,000 as of its most recent filing with the SEC.
Other hedge funds also recently bought and sold shares of the company. Creative Planning increased its stake in C R Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock valued at $1,068,000 after buying an additional 29 shares during the last quarter. UBS Asset Management Americas Inc. increased its stake in C R Bard by 3.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 267,451 shares of the medical instruments supplier’s stock valued at $60,087,000 after buying an additional 9,134 shares during the last quarter. Granite Investment Advisors LLC increased its stake in C R Bard by 14.3% in the first quarter. Granite Investment Advisors LLC now owns 33,276 shares of the medical instruments supplier’s stock valued at $8,270,000 after buying an additional 4,159 shares during the last quarter. State Street Corp increased its stake in C R Bard by 5.0% in the fourth quarter. State Street Corp now owns 3,703,576 shares of the medical instruments supplier’s stock valued at $832,035,000 after buying an additional 176,151 shares during the last quarter. Finally, Fundsmith LLP increased its stake in C R Bard by 2.1% in the first quarter. Fundsmith LLP now owns 2,553,141 shares of the medical instruments supplier’s stock valued at $633,996,000 after buying an additional 52,272 shares during the last quarter. Hedge funds and other institutional investors own 86.89% of the company’s stock.
C R Bard Inc (NYSE BCR) traded up 0.29% during trading on Friday, reaching $314.79. The company had a trading volume of 113,918 shares. The company has a 50 day moving average price of $304.88 and a 200 day moving average price of $253.11. The company has a market capitalization of $22.80 billion, a PE ratio of 40.06 and a beta of 0.63. C R Bard Inc has a 52-week low of $203.63 and a 52-week high of $314.86.
C R Bard (NYSE:BCR) last announced its earnings results on Sunday, April 23rd. The medical instruments supplier reported $2.87 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.65 by $0.22. C R Bard had a return on equity of 48.48% and a net margin of 14.31%. The business had revenue of $938.80 million for the quarter, compared to analyst estimates of $916.15 million. During the same quarter last year, the firm earned $2.34 EPS. C R Bard’s revenue for the quarter was up 7.5% compared to the same quarter last year. On average, equities analysts forecast that C R Bard Inc will post $11.78 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, May 12th. Shareholders of record on Monday, May 1st were given a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a dividend yield of 0.33%. The ex-dividend date was Thursday, April 27th. C R Bard’s dividend payout ratio (DPR) is 14.77%.
Several analysts have issued reports on BCR shares. Zacks Investment Research upgraded C R Bard from a “hold” rating to a “buy” rating and set a $276.00 price objective on the stock in a report on Friday, March 3rd. BMO Capital Markets restated a “buy” rating and set a $255.00 price objective on shares of C R Bard in a report on Tuesday, April 11th. Jefferies Group LLC restated a “hold” rating and set a $237.00 price objective on shares of C R Bard in a report on Monday, March 27th. Raymond James Financial, Inc. downgraded C R Bard from a “strong-buy” rating to a “mkt perform” rating in a report on Wednesday, April 26th. Finally, Wells Fargo & Co downgraded C R Bard from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 25th. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $265.62.
In other C R Bard news, VP Frank Lupisella, Jr. sold 3,622 shares of the business’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $304.00, for a total transaction of $1,101,088.00. Following the transaction, the vice president now owns 10,139 shares of the company’s stock, valued at approximately $3,082,256. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.97% of the stock is owned by insiders.
About C R Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C R Bard Inc (NYSE:BCR).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/glenview-trust-co-has-867000-position-in-c-r-bard-inc-bcr/1895032.html
Receive News & Ratings for C R Bard Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard Inc and related companies with MarketBeat.com's FREE daily email newsletter.